Risk of Strongyloides Hyperinfection Syndrome when prescribing dexamethasone in severe COVID-19
Strongyloides stercoralis, a parasitic nematode infection endemic in tropical and subtropical regions, is estimated to infect 30 to 100 million people worldwide. Patients deemed at high risk (migrants with high risk exposure) may need empirical treatment with ivermectin, which has an efficacy of 85%...
Gespeichert in:
| Veröffentlicht in: | Travel medicine and infectious disease 2021-03, Vol.40, p.101981-101981, Article 101981 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 101981 |
|---|---|
| container_issue | |
| container_start_page | 101981 |
| container_title | Travel medicine and infectious disease |
| container_volume | 40 |
| creator | De Wilton, Angus Nabarro, Laura E. Godbole, Gauri S. Chiodini, Peter L. Boyd, Aileen Woods, Katherine |
| description | Strongyloides stercoralis, a parasitic nematode infection endemic in tropical and subtropical regions, is estimated to infect 30 to 100 million people worldwide. Patients deemed at high risk (migrants with high risk exposure) may need empirical treatment with ivermectin, which has an efficacy of 85% as a single dose [5]. COVID-19 patients with undiagnosed Strongyloides infection undergoing immunosuppression are at risk of developing SHS.Funding source PLC is supported by the UCL Hospitals Comprehensive Biomedical Research Centre.CRediT author contribution statement Conceptualisation: A de W. Writing-review and editing by all authors.Declaration of competing interest The authors have no competing interests to declare. |
| doi_str_mv | 10.1016/j.tmaid.2021.101981 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7847532</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1477893921000223</els_id><sourcerecordid>2504346908</sourcerecordid><originalsourceid>FETCH-LOGICAL-c487t-ce10ffce3ade839f914340e6c4248c31a8a0c43b7f8136d354985d1e3cfa2ed63</originalsourceid><addsrcrecordid>eNp9kU9rGzEQxUVoSdK0nyAQBD2vK-1od7WHFIr7J4FAIEl7FbI0suV4JVdau_W3r1ynob30pEHz5s1jfoScczbhjLfvlpNx0N5Oalbz_U8v-RE55bKDiglRvyi16LpK9tCfkFc5LxmDRgo4JicADTSctadE3fn8SKOj92OKYb5bRW8x06vdGpMPDs3oY6D3u2BTHJD-WGCg64TZJD_zYU4t_tQDjgudY0DqA824xYR0evvt-mPF-9fkpdOrjG-e3jPy9fOnh-lVdXP75Xr64aYyQnZjZZAz5wyCtiihdz0XIBi2RtRCGuBaamYEzDonObQWGtHLxnIE43SNtoUz8v7gu97MBrQGw5j0Sq2TH3Taqai9-rcT_ELN41Z1UnQN1MXg7ZNBit83mEe1jJsUSmZVN6ykaXsmiwoOKpNizgnd8wbO1J6KWqrfVNSeijpQKVMXf4d7nvmDoQguDwIsJ9p6TCobj8Gg9akgUDb6_y74BTfioLI</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2504346908</pqid></control><display><type>article</type><title>Risk of Strongyloides Hyperinfection Syndrome when prescribing dexamethasone in severe COVID-19</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><source>ProQuest Central UK/Ireland</source><creator>De Wilton, Angus ; Nabarro, Laura E. ; Godbole, Gauri S. ; Chiodini, Peter L. ; Boyd, Aileen ; Woods, Katherine</creator><creatorcontrib>De Wilton, Angus ; Nabarro, Laura E. ; Godbole, Gauri S. ; Chiodini, Peter L. ; Boyd, Aileen ; Woods, Katherine</creatorcontrib><description>Strongyloides stercoralis, a parasitic nematode infection endemic in tropical and subtropical regions, is estimated to infect 30 to 100 million people worldwide. Patients deemed at high risk (migrants with high risk exposure) may need empirical treatment with ivermectin, which has an efficacy of 85% as a single dose [5]. COVID-19 patients with undiagnosed Strongyloides infection undergoing immunosuppression are at risk of developing SHS.Funding source PLC is supported by the UCL Hospitals Comprehensive Biomedical Research Centre.CRediT author contribution statement Conceptualisation: A de W. Writing-review and editing by all authors.Declaration of competing interest The authors have no competing interests to declare.</description><identifier>ISSN: 1477-8939</identifier><identifier>EISSN: 1873-0442</identifier><identifier>DOI: 10.1016/j.tmaid.2021.101981</identifier><identifier>PMID: 33535106</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Animals ; Asymptomatic ; Coronaviruses ; Correspondence ; COVID-19 ; COVID-19 Drug Treatment ; Dexamethasone - adverse effects ; Dyspnea ; Fever ; Humans ; Infections ; Infectious diseases ; Microscopy ; Prisoners of war & missing in action ; SARS-CoV-2 ; Sepsis ; Serology ; Severe acute respiratory syndrome coronavirus 2 ; Steroids ; Strongyloides ; Strongyloides stercoralis ; Strongyloidiasis - drug therapy ; Travel medicine ; Tropical climate</subject><ispartof>Travel medicine and infectious disease, 2021-03, Vol.40, p.101981-101981, Article 101981</ispartof><rights>2021 Elsevier Ltd</rights><rights>2021. Elsevier Ltd</rights><rights>2021 Elsevier Ltd. All rights reserved. 2021 Elsevier Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c487t-ce10ffce3ade839f914340e6c4248c31a8a0c43b7f8136d354985d1e3cfa2ed63</citedby><cites>FETCH-LOGICAL-c487t-ce10ffce3ade839f914340e6c4248c31a8a0c43b7f8136d354985d1e3cfa2ed63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/2504346908?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>230,314,780,784,885,3550,27924,27925,45995,64385,64389,72469</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33535106$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>De Wilton, Angus</creatorcontrib><creatorcontrib>Nabarro, Laura E.</creatorcontrib><creatorcontrib>Godbole, Gauri S.</creatorcontrib><creatorcontrib>Chiodini, Peter L.</creatorcontrib><creatorcontrib>Boyd, Aileen</creatorcontrib><creatorcontrib>Woods, Katherine</creatorcontrib><title>Risk of Strongyloides Hyperinfection Syndrome when prescribing dexamethasone in severe COVID-19</title><title>Travel medicine and infectious disease</title><addtitle>Travel Med Infect Dis</addtitle><description>Strongyloides stercoralis, a parasitic nematode infection endemic in tropical and subtropical regions, is estimated to infect 30 to 100 million people worldwide. Patients deemed at high risk (migrants with high risk exposure) may need empirical treatment with ivermectin, which has an efficacy of 85% as a single dose [5]. COVID-19 patients with undiagnosed Strongyloides infection undergoing immunosuppression are at risk of developing SHS.Funding source PLC is supported by the UCL Hospitals Comprehensive Biomedical Research Centre.CRediT author contribution statement Conceptualisation: A de W. Writing-review and editing by all authors.Declaration of competing interest The authors have no competing interests to declare.</description><subject>Animals</subject><subject>Asymptomatic</subject><subject>Coronaviruses</subject><subject>Correspondence</subject><subject>COVID-19</subject><subject>COVID-19 Drug Treatment</subject><subject>Dexamethasone - adverse effects</subject><subject>Dyspnea</subject><subject>Fever</subject><subject>Humans</subject><subject>Infections</subject><subject>Infectious diseases</subject><subject>Microscopy</subject><subject>Prisoners of war & missing in action</subject><subject>SARS-CoV-2</subject><subject>Sepsis</subject><subject>Serology</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Steroids</subject><subject>Strongyloides</subject><subject>Strongyloides stercoralis</subject><subject>Strongyloidiasis - drug therapy</subject><subject>Travel medicine</subject><subject>Tropical climate</subject><issn>1477-8939</issn><issn>1873-0442</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp9kU9rGzEQxUVoSdK0nyAQBD2vK-1od7WHFIr7J4FAIEl7FbI0suV4JVdau_W3r1ynob30pEHz5s1jfoScczbhjLfvlpNx0N5Oalbz_U8v-RE55bKDiglRvyi16LpK9tCfkFc5LxmDRgo4JicADTSctadE3fn8SKOj92OKYb5bRW8x06vdGpMPDs3oY6D3u2BTHJD-WGCg64TZJD_zYU4t_tQDjgudY0DqA824xYR0evvt-mPF-9fkpdOrjG-e3jPy9fOnh-lVdXP75Xr64aYyQnZjZZAz5wyCtiihdz0XIBi2RtRCGuBaamYEzDonObQWGtHLxnIE43SNtoUz8v7gu97MBrQGw5j0Sq2TH3Taqai9-rcT_ELN41Z1UnQN1MXg7ZNBit83mEe1jJsUSmZVN6ykaXsmiwoOKpNizgnd8wbO1J6KWqrfVNSeijpQKVMXf4d7nvmDoQguDwIsJ9p6TCobj8Gg9akgUDb6_y74BTfioLI</recordid><startdate>20210301</startdate><enddate>20210301</enddate><creator>De Wilton, Angus</creator><creator>Nabarro, Laura E.</creator><creator>Godbole, Gauri S.</creator><creator>Chiodini, Peter L.</creator><creator>Boyd, Aileen</creator><creator>Woods, Katherine</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>F1W</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H95</scope><scope>H97</scope><scope>K9.</scope><scope>KB0</scope><scope>L.G</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>5PM</scope></search><sort><creationdate>20210301</creationdate><title>Risk of Strongyloides Hyperinfection Syndrome when prescribing dexamethasone in severe COVID-19</title><author>De Wilton, Angus ; Nabarro, Laura E. ; Godbole, Gauri S. ; Chiodini, Peter L. ; Boyd, Aileen ; Woods, Katherine</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c487t-ce10ffce3ade839f914340e6c4248c31a8a0c43b7f8136d354985d1e3cfa2ed63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Animals</topic><topic>Asymptomatic</topic><topic>Coronaviruses</topic><topic>Correspondence</topic><topic>COVID-19</topic><topic>COVID-19 Drug Treatment</topic><topic>Dexamethasone - adverse effects</topic><topic>Dyspnea</topic><topic>Fever</topic><topic>Humans</topic><topic>Infections</topic><topic>Infectious diseases</topic><topic>Microscopy</topic><topic>Prisoners of war & missing in action</topic><topic>SARS-CoV-2</topic><topic>Sepsis</topic><topic>Serology</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Steroids</topic><topic>Strongyloides</topic><topic>Strongyloides stercoralis</topic><topic>Strongyloidiasis - drug therapy</topic><topic>Travel medicine</topic><topic>Tropical climate</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>De Wilton, Angus</creatorcontrib><creatorcontrib>Nabarro, Laura E.</creatorcontrib><creatorcontrib>Godbole, Gauri S.</creatorcontrib><creatorcontrib>Chiodini, Peter L.</creatorcontrib><creatorcontrib>Boyd, Aileen</creatorcontrib><creatorcontrib>Woods, Katherine</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ASFA: Aquatic Sciences and Fisheries Abstracts</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>Aquatic Science & Fisheries Abstracts (ASFA) 1: Biological Sciences & Living Resources</collection><collection>Aquatic Science & Fisheries Abstracts (ASFA) 3: Aquatic Pollution & Environmental Quality</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Aquatic Science & Fisheries Abstracts (ASFA) Professional</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Travel medicine and infectious disease</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>De Wilton, Angus</au><au>Nabarro, Laura E.</au><au>Godbole, Gauri S.</au><au>Chiodini, Peter L.</au><au>Boyd, Aileen</au><au>Woods, Katherine</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Risk of Strongyloides Hyperinfection Syndrome when prescribing dexamethasone in severe COVID-19</atitle><jtitle>Travel medicine and infectious disease</jtitle><addtitle>Travel Med Infect Dis</addtitle><date>2021-03-01</date><risdate>2021</risdate><volume>40</volume><spage>101981</spage><epage>101981</epage><pages>101981-101981</pages><artnum>101981</artnum><issn>1477-8939</issn><eissn>1873-0442</eissn><abstract>Strongyloides stercoralis, a parasitic nematode infection endemic in tropical and subtropical regions, is estimated to infect 30 to 100 million people worldwide. Patients deemed at high risk (migrants with high risk exposure) may need empirical treatment with ivermectin, which has an efficacy of 85% as a single dose [5]. COVID-19 patients with undiagnosed Strongyloides infection undergoing immunosuppression are at risk of developing SHS.Funding source PLC is supported by the UCL Hospitals Comprehensive Biomedical Research Centre.CRediT author contribution statement Conceptualisation: A de W. Writing-review and editing by all authors.Declaration of competing interest The authors have no competing interests to declare.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>33535106</pmid><doi>10.1016/j.tmaid.2021.101981</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1477-8939 |
| ispartof | Travel medicine and infectious disease, 2021-03, Vol.40, p.101981-101981, Article 101981 |
| issn | 1477-8939 1873-0442 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7847532 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present); ProQuest Central UK/Ireland |
| subjects | Animals Asymptomatic Coronaviruses Correspondence COVID-19 COVID-19 Drug Treatment Dexamethasone - adverse effects Dyspnea Fever Humans Infections Infectious diseases Microscopy Prisoners of war & missing in action SARS-CoV-2 Sepsis Serology Severe acute respiratory syndrome coronavirus 2 Steroids Strongyloides Strongyloides stercoralis Strongyloidiasis - drug therapy Travel medicine Tropical climate |
| title | Risk of Strongyloides Hyperinfection Syndrome when prescribing dexamethasone in severe COVID-19 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T08%3A32%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Risk%20of%20Strongyloides%20Hyperinfection%20Syndrome%20when%20prescribing%20dexamethasone%20in%20severe%20COVID-19&rft.jtitle=Travel%20medicine%20and%20infectious%20disease&rft.au=De%20Wilton,%20Angus&rft.date=2021-03-01&rft.volume=40&rft.spage=101981&rft.epage=101981&rft.pages=101981-101981&rft.artnum=101981&rft.issn=1477-8939&rft.eissn=1873-0442&rft_id=info:doi/10.1016/j.tmaid.2021.101981&rft_dat=%3Cproquest_pubme%3E2504346908%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2504346908&rft_id=info:pmid/33535106&rft_els_id=S1477893921000223&rfr_iscdi=true |